- Home
- REVB vs ELAB Comparison
REVB vs ELAB Comparison
Compare REVB & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- ELAB
- Stock Information
- Founded
- REVB 2020
- ELAB 2020
- Country
- REVB United States
- ELAB United States
- Employees
- REVB N/A
- ELAB N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- ELAB
- Sector
- REVB Health Care
- ELAB
- Exchange
- REVB Nasdaq
- ELAB Nasdaq
- Market Cap
- REVB 3.8M
- ELAB 3.2M
- IPO Year
- REVB N/A
- ELAB 2023
- Fundamental
- Price
- REVB $2.88
- ELAB $2.28
- Analyst Decision
- REVB
- ELAB
- Analyst Count
- REVB 0
- ELAB 0
- Target Price
- REVB N/A
- ELAB N/A
- AVG Volume (30 Days)
- REVB 269.2K
- ELAB 180.3K
- Earning Date
- REVB 08-08-2025
- ELAB 08-13-2025
- Dividend Yield
- REVB N/A
- ELAB N/A
- EPS Growth
- REVB N/A
- ELAB N/A
- EPS
- REVB N/A
- ELAB N/A
- Revenue
- REVB N/A
- ELAB N/A
- Revenue This Year
- REVB N/A
- ELAB N/A
- Revenue Next Year
- REVB N/A
- ELAB N/A
- P/E Ratio
- REVB N/A
- ELAB N/A
- Revenue Growth
- REVB N/A
- ELAB N/A
- 52 Week Low
- REVB $2.11
- ELAB $1.95
- 52 Week High
- REVB $168.00
- ELAB $660.80
- Technical
- Relative Strength Index (RSI)
- REVB 44.79
- ELAB 48.70
- Support Level
- REVB $2.97
- ELAB $2.20
- Resistance Level
- REVB $3.18
- ELAB $2.47
- Average True Range (ATR)
- REVB 0.23
- ELAB 0.21
- MACD
- REVB 0.13
- ELAB 0.00
- Stochastic Oscillator
- REVB 60.37
- ELAB 14.08
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.